XELOX和OLF化疗方案治疗K-ras基因突变型老年晚期大肠癌的疗效分析

发布时间：2018-04-08 21:28

本文选题：K-ras基因　切入点：大肠癌　出处：《中国现代医学杂志》2016年02期

【摘要】：目的比较分析K-ras基因突变型老年晚期大肠癌患者接受奥沙利铂联合卡培他滨(XELOX)和奥沙利铂联合氟尿嘧啶(OLF)化疗方案的疗效。方法分析2009年1月-2012年8月该院收治的经基因分析确诊为K-ras基因突变型晚期大肠癌病例,共106例。其中接受XELOX化疗者56例,接受OLF化疗者50例,并比较分析两组接受化疗后发生毒副反应、客观缓解率、疾病控制率、无进展生存期、总生存期的差异。结果O LF组骨髓抑制、恶心呕吐、静脉炎、心脏毒性的发生率高于XELO X组,而腹泻的发生率XELO X组要明显高于OLF组,在口腔炎及神经毒性的发生率上,两组差异无统计学意义。两组客观缓解率、疾病控制率、无进展生存期和总生存期差异无统计学意义。结论 XELOX治疗K-ras基因突变型老年晚期结肠癌具一定疗效,相对安全,可提高患者的生存质量。
[Abstract]:Objective to compare the efficacy of oxaliplatin combined with capecitabine XELOX and oxaliplatin combined with fluorouracil in elderly patients with advanced colorectal cancer with K-ras gene mutation.Methods from January 2009 to August 2012, 106 patients with advanced colorectal cancer with K-ras gene mutation diagnosed by gene analysis in our hospital were analyzed.56 cases received XELOX chemotherapy and 50 cases received OLF chemotherapy. The differences of side effects, objective remission rate, disease control rate, progression free survival time and total survival time were compared between the two groups.Results the incidence of bone marrow suppression, nausea, vomiting, phlebitis and cardiac toxicity in OLF group was higher than that in XELO X group, while the incidence of diarrhea in XELO X group was significantly higher than that in OLF group. There was no significant difference in the incidence of stomatitis and neurotoxicity between the two groups.There was no significant difference in objective remission rate, disease control rate, progression free survival and total survival between the two groups.Conclusion XELOX is effective and safe in the treatment of advanced colon cancer with K-ras gene mutation. It can improve the quality of life of the patients.
【作者单位】：广东省肇庆市第一人民医院肿瘤科;
【分类号】：R735.34

【相似文献】